Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Update

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 6,060,000 shares, an increase of 7.3% from the March 15th total of 5,650,000 shares. Currently, 12.3% of the shares of the stock are sold short. Based on an average daily volume of 540,200 shares, the short-interest ratio is currently 11.2 days.

Deciphera Pharmaceuticals Trading Down 0.8 %

DCPH stock traded down $0.12 during mid-day trading on Wednesday, reaching $14.72. The company’s stock had a trading volume of 304,313 shares, compared to its average volume of 520,367. The stock has a market cap of $1.19 billion, a PE ratio of -6.43 and a beta of 0.39. Deciphera Pharmaceuticals has a fifty-two week low of $9.90 and a fifty-two week high of $17.73. The company’s 50 day moving average is $15.68 and its two-hundred day moving average is $14.19.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. Deciphera Pharmaceuticals’s quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.60) EPS. On average, analysts forecast that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Institutional Trading of Deciphera Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter valued at approximately $30,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after buying an additional 997 shares during the period. Compass Wealth Management LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter valued at approximately $70,000. Advisor Group Holdings Inc. grew its stake in shares of Deciphera Pharmaceuticals by 78.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company’s stock valued at $71,000 after buying an additional 1,898 shares during the period. Finally, AJOVista LLC purchased a new position in shares of Deciphera Pharmaceuticals during the 4th quarter worth approximately $76,000. Hedge funds and other institutional investors own 70.96% of the company’s stock.

Analyst Upgrades and Downgrades

DCPH has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Stifel Nicolaus upped their price target on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.